Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.34 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3304453 | 0.87 | PTGDR2 (0.46) | PTGDR2 | |
| SCHEMBL3570130 | 0.87 | PTGDR2 (0.56) | PTGDR2AKR1B1PTGS2PTGDRAKR1C3 | |
| SCHEMBL2770201 | 0.86 | PTGDR2 (0.75) | PTGDR2AKR1B1PTGDR | |
| SCHEMBL3577547 | 0.85 | PTGDR2 (0.65) | PTGDR2AKR1B1PTGDR | |
| SCHEMBL2769501 | 0.84 | PTGDR2 (0.64) | PTGDR2PTGDR | |
| SCHEMBL3299837 | 0.83 | PTGDR2 (0.53) | PTGDR2AKR1B1PTGDRAGBL2AKR1C3 | |
| SCHEMBL2769764 | 0.82 | PTGDR2 (0.57) | PTGDR2PTGDR | |
| SCHEMBL3332659 | 0.82 | PTGDR2 (0.52) | PTGDR2AKR1C3AKR1C2 | |
| SCHEMBL3299818 | 0.81 | PTGDR2 (0.52) | PTGDR2 | |
| SCHEMBL3577489 | 0.81 | PTGDR2 (0.60) | PTGDR2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010034-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2010-01-14 | — | — | US | claimed |
| US-20100010034-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010034-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010034-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010034-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| EP-2094266-A1 | CRTH2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2009-09-02 | — | — | EP | disclosed |
| EP-2094266-A1 | CRTH2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074966-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074966-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074966-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010034-A1 | CRTH2 ANTAGONISTS | HRH2, MDH2, HRH1 | PTGDR2 167/4885AKR1B1 2286/4885PTGS2 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.